Clinical and Metabolic Studies with Imipramine in Man
Abstract
Six out of seven severely depressed patients improved rapidly on very high doses of imipramine. Clinical improvement correlated well with drug blood levels, which varied greatly from patient to patient and were characteristic of individual patients rather than of dose. Three out of five of the same patients receiving a combination of presumptive inhibitors of drug-metabolizing enzymes and imipramine had drug blood levels comparable to those of two patients receiving high doses of imipramine alone. Further study is underway to clarify the human pharmacology of these two therapies.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
